On 12 November, AlzeCure Pharma AB, a Swedish pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, announced that its has received approval to initiate a Phase I clinical trial with ACD856, one of its therapy candidates for Alzheimer’s disease (AD). Approval has been received from the regulatory authorities in Sweden. The primary study objective of this trial is to evaluate the drug candidate's tolerability and safety.
"It is gratifying that just a few months after we completed our first clinical study with positive results, we now have all regulatory approvals in place to be able to start a second study with our primary candidate ACD856. Cognitive disorders, and especially Alzheimer's disease, is a disease area in great need of new and more effective treatments, and I am very much looking forward to the continued development of this important drug candidate", said Martin Jönsson, CEO of AlzeCure Pharma AB.
